It is made available under a CC-BY-NC-ND 4.0 International license .

# 1 TITLE: Emergence and spread of two SARS-CoV-2 variants of interest 2 in Nigeria.

3

4 Idowu B. Olawoye<sup>1,2\*</sup>, Paul E. Oluniyi<sup>1,2\*</sup>, Judith U. Oguzie<sup>1,2\*</sup>, Jessica N. Uwanibe<sup>1,2\*</sup>, Adeyemi T. Kayode<sup>1,2\*</sup>, Testimony J. Olumade<sup>1,2\*</sup>, Fehintola V. Ajogbasile<sup>1,2\*</sup>, Edyth Parker<sup>3\*</sup>, Philomena E. 5 6 Eromon<sup>2</sup>, Priscilla Abechi<sup>1,2</sup>, Tope Sobajo<sup>1,2</sup>, Chinedu Ugwu<sup>1,2</sup>, George Uwem<sup>1,2</sup>, Femi Ayoade<sup>1,2</sup> 7 , Kazeem Akano<sup>1,2</sup>, Nicholas Oyejide<sup>2</sup>, Iyanuoluwa Fred-Akintunwa<sup>2</sup>, Kemi Adedotun-Sulaiman<sup>2</sup> 8 Farida Brimmo<sup>2</sup>, Benjamin Adegboyega<sup>2</sup>, Courage Philip<sup>2</sup>, Ayomide Adeleke<sup>2</sup>, Grace C. 9 Chukwu<sup>2</sup>, Ahmed I. Muhammad<sup>2</sup>, Oludayo O. Ope-ewe<sup>2</sup>, Shobi Otitoola<sup>2</sup>, Olusola A. 10 Ogunsanya<sup>2</sup>, Mudasiru F. Saibu<sup>2</sup>, Ayotunde E. Sijuwola<sup>2</sup>, Grace O. Ezekiel<sup>2</sup>, Oluwagboadurami 11 G. John<sup>1,2</sup>, Julie O. Akin-John<sup>1,2</sup>, Oluwasemilogo O. Akinlo<sup>2</sup>, Olanrewaju O. Fayemi<sup>2</sup>, Testimony O. Ipaye<sup>2</sup>, Deborah C. Nwodo<sup>2</sup>, Abolade E. Omoniyi<sup>2</sup>, Iyobosa B. Omwanghe<sup>2</sup>, Christabel A. 12 13 Terkuma<sup>2</sup>, Johnson Okolie<sup>2</sup>, Olubukola Ayo-Ale<sup>2</sup>, Odia Ikponmwosa<sup>4</sup>, Ebo Benevolence<sup>4</sup>, 14 Okonofua Naregose<sup>4</sup>, Akhilomen Patience<sup>4</sup>, Osiemi Blessing<sup>4</sup>, Airende Micheal<sup>4</sup>, Agbukor 15 Jacqueline<sup>4</sup>, Aiyepada John<sup>4</sup>, Paulson Ebhodaghe<sup>4</sup>, Omiunu Racheal<sup>4</sup>, Esumeh Rita<sup>4</sup>, Giwa 16 Rosemary<sup>4</sup>, Ehikhametalor Solomon<sup>4</sup>, Ekanem Anieno<sup>4</sup>, Yerumoh Edna<sup>4</sup>, Aire Chris<sup>4</sup>, Adomeh 17 Donatus<sup>4</sup>, Ephraim Ogbaini<sup>4</sup>, Mirabeau Y. Tatfeng<sup>5</sup>, Hannah E. Omunakwe<sup>6</sup>, Mienye Bob-18 Manuel<sup>6</sup>, Rahaman Ahmed<sup>7</sup>, Chika Onwuamah<sup>7</sup>, Joseph Shaibu<sup>7</sup>, Azuka Okwuraiwe<sup>7</sup>, Anthony 19 E. Atage<sup>8</sup>, Andrew Bock-Oruma<sup>9</sup>, Funmi Daramola<sup>10</sup>, Akinwumi Fajola<sup>11</sup>, Nsikak-Abasi Ntia<sup>12</sup>, Julie J. Ekpo<sup>13</sup>, Anietie Moses<sup>13</sup>, Worbianueri B. Moore-Igwe<sup>14</sup>, Ibrahim F. Yusuf<sup>10</sup>, Enoch O. Fakayode<sup>15</sup>, Monilade Akinola<sup>16</sup>, Ibrahim Kida<sup>17</sup>, Bamidele S. Oderinde<sup>17</sup>, Zara Wudiri<sup>18</sup>, Olufemi O. Adeyemi<sup>19</sup>, Olusola Akanbi<sup>20</sup>, Anthony Ahumibe<sup>20</sup>, Afolabi Akinpelu<sup>20</sup>, Oyeronke Ayansola<sup>20</sup>, 20 21 22 23 O. Adeyemi<sup>19</sup>, Olusola Akanbi<sup>20</sup>, Anthony Ahumibe<sup>20</sup>, Atolabi Akinpelu<sup>20</sup>, Oyeronke Ayansola , Olajumoke Babatunde<sup>20</sup>, Adesuyi Omoare<sup>20</sup>, Chimaobi Chukwu<sup>20</sup>, Nwando Mba<sup>20</sup>, Ewean C. Omoruyi<sup>21</sup>, Johnson A. Adeniji<sup>22</sup>, Moses O. Adewunmi<sup>22</sup>, Oluseyi Olayinka<sup>22</sup>, Olisa Olasunkanmi<sup>23</sup>, Olatunji Akande<sup>23</sup>, Ifeanyi Nwafor<sup>24</sup>, Matthew Ekeh<sup>24</sup>, Erim Ndoma<sup>24</sup>, Richard Ewah<sup>24</sup>, Rosemary Duruihuoma<sup>24</sup>, Augustine Abu<sup>24</sup>, Elizabeth Odeh<sup>24</sup>, Venatious Onyia<sup>24</sup>, Kingsley C. Ojide<sup>24</sup>, Sylvanus Okoro<sup>25</sup>, Daniel Igwe<sup>25</sup>, Kamran Khan<sup>34</sup>, Anthony N. Ajayi<sup>26</sup>, Ebhodaghe Ngozi Ugwu<sup>27</sup>, Collins N. Ugwu<sup>26</sup>, Kingsley Ukwuaja<sup>26</sup>, Emeka O. Ogah<sup>25</sup>, Chukwuyem Abejegah<sup>28</sup>, Nelson Adedosu<sup>28</sup>, Olufemi Ayodeji<sup>28</sup>, Rafiu O. Isamotu<sup>29</sup>, Galadima Cadrama<sup>30</sup> Brittany Petros<sup>31</sup> Katherine J. Siddle<sup>31</sup> Stephen Schaffner<sup>31</sup> George Akpede<sup>4</sup> Cyril 24 25 26 27 28 29 30 Gadzama<sup>30</sup>, Brittany Petros<sup>31</sup>, Katherine J. Siddle<sup>31</sup>, Stephen Schaffner<sup>31</sup>, George Akpede<sup>4</sup>, Cyril 31 Oshomah Erameh<sup>4</sup>, Marycelin Baba<sup>16,17</sup>, Femi Oladiji<sup>32</sup>, Rosemary Audu<sup>7</sup>, Nnaemeka Ndodo<sup>20</sup>, 32 Adeola Fowotade<sup>23</sup>, Sylvanus Okogbenin<sup>4</sup>, Peter Okokhere<sup>4</sup>, Danny Park<sup>31</sup>, Bronwyn Mcannis<sup>31</sup>, Ifedayo Adetifa<sup>20</sup>, Chikwe Ihekweazu<sup>20</sup>, Babatunde L. Salako<sup>7</sup>, Oyewale Tomori<sup>2</sup>, Anise N. 33 34 Happi<sup>2</sup>, Onikepe A. Folarin<sup>1,2</sup>, Kristian G. Andersen<sup>3</sup>, Pardis C. Sabeti<sup>31,33</sup>, Christian T. Happi<sup>1,2,33‡</sup> 35 36

- 37
- 38
- 39 1. Department of Biological Sciences, Faculty of Natural Sciences, Redeemer's University, Ede,40 Osun State, Nigeria.
- 41 2. African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's
  42 University, Ede, Osun State, Nigeria.
- 43 3. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA,44 USA.
- 45 4. Irrua Specialist Teaching Hospital, Edo State, Nigeria.
- 46 5. Department of Medical Laboratory Science, Niger Delta University, Bayelsa State, Nigeria.
- 47 6. Satellite Molecular Laboratory, Rivers State University Teaching Hospital, Port Harcourt,
- 48 Rivers State, Nigeria.
- 49 7. The Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.

#### It is made available under a CC-BY-NC-ND 4.0 International license .

- 50 8. Molecular Laboratory, Regional Centre for Biotechnology and Bioresources Research,
- 51 University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
- 52 9. Family Physician, SPDC, Port Harcourt, Rivers State, Nigeria.
- 53 10. Clinical Health, SPDC, Port Harcourt, Rivers State, Nigeria.
- 54 11. Regional Community Health, SPDC, Port Harcourt, Rivers State, Nigeria.
- 55 12. Occupational Health, SPDC, Port Harcourt, Rivers State, Nigeria.
- 56 13. Department of Medical Microbiology and Parasitology, University of Uyo, Akwa Ibom State,57 Nigeria.
- 58 14. Rivers State University, Port Harcourt, Rivers State, Nigeria.
- 59 15. Department of Public Health, Ministry of Health, Ilorin, Kwara State, Nigeria.
- 60 16. WHO Polio Laboratory, University of Maiduguri Teaching Hospital, Maiduguri, Borno State,
   61 Nigeria.
- 62 17. Department of Immunology, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
- 63 18. Department of Community Medicine, University of Maiduguri Teaching Hospital, Maiduguri,64 Borno State, Nigeria.
- 19. Department of Medical Microbiology and Parasitology. Faculty of Basic Clinical Sciences.
- 66 College of Health Sciences, University of Ilorin. Ilorin, Kwara State, Nigeria.
- 67 20. Nigeria Centre for Disease Control, Abuja, Nigeria.
- 68 21. Medical Microbiology and Parasitology Department, College of Medicine, University of 69 Ibadan, Ibadan, Nigeria.
- 70 22. Department of Virology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
- 71 23. Biorepository Clinical Virology Laboratory, University of Ibadan, Ibadan, Nigeria.
- 72 24. Virology Laboratory, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi
   73 State, Nigeria.
- 74 25. Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria.
- 75 26. Internal Medicine Department, Alex Ekwueme Federal University Teaching Hospital, 76 Abakaliki, Nigeria.
- 27. Haematology Department, Alex Ekwueme Federal University Teaching Hospital, Abakaliki,Nigeria.
- 79 28. Federal Medical Center, Owo, Ondo State, Nigeria
- 80 29. Ministry of Health, Osun State, Nigeria.
- 81 30. Department of Medical Microbiology, University of Maiduguri Teaching Hospital, Maiduguri,
- 82 Borno State, Nigeria.
- 83 31. Broad Institute of Harvard and MIT, Cambridge, MA, USA.
- 32. Department of Epidemiology and Community Health, Faculty of Clinical Sciences, College of
- 85 Health Sciences, University of Ilorin, Ilorin, Nigeria.
- 86 33. Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public
- 87 Health, Boston, MA, USA.
- **88 34**. Bluedot, Toronto, Canada
- 89
- 90 \*These authors contributed equally.
- 91 ‡ Correspondence (happic@run.edu.ng)

92 93

94 95

It is made available under a CC-BY-NC-ND 4.0 International license .

- 101
- 102

## 103 Abstract

104

105 Identifying the dissemination patterns and impacts of a virus of economic or health importance 106 during a pandemic is crucial, as it informs the public on policies for containment in order to 107 reduce the spread of the virus. In this study, we integrated genomic and travel data to 108 investigate the emergence and spread of the B.1.1.318 and B.1.525 variants of interest in 109 Nigeria and the wider Africa region. By integrating travel data and phylogeographic 110 reconstructions, we find that these two variants that arose during the second wave emerged 111 from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. 112 Our results show how regional connectivity in downsampled regions like Africa can often 113 influence virus transmissions between neighbouring countries. Our findings demonstrate the 114 power of genomic analysis when combined with mobility and epidemiological data to identify the 115 drivers of transmission in the region, generating actionable information for public health decision 116 makers in the region.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 117 Introduction

With a population of over 200 million, Nigeria is the most populous country in Africa<sup>1</sup>. Since 118 119 the first report of SARS-CoV-2 in Nigeria on the 27th of February 2020, the cumulative 120 number of confirmed COVID-19 cases in Nigeria has risen to more than 265 000 as of mid-September 2022<sup>2</sup>. However, this burden is extremely low relative to SARS-Cov-2 infections 121 122 in the rest of the world. Adjusting for population size, there have been 129 cases per 100 123 000 people in Nigeria as of mid-September, compared to more than 34 700 and 28 700 in 124 the UK and USA, and 2340 and 711 in Indonesia and Pakistan, respectively. Concurrently, 125 Nigeria has also only had a little over 3000 reported deaths (2 per 100 000), compared to the 126 UK and USA, which had 303 and 315 cumulative deaths per 100 000 people<sup>2</sup>. This relatively 127 low but heterogeneous incidence in Nigeria and across the wider African region has been 128 the cause of persistent speculation, including on the putative central role of case underascertainment<sup>3,4,5</sup>. The underlying cause remains understudied and is likely 129 multifactorial, with many other factors speculated to contribute, including skewed age 130 structures of populations, more restricted human mobility in certain regions, host genetics, 131 132 environmental factors, and potential pre-existing population immunity to related viruses<sup>6,7</sup>. 133 Before the emergence of globally sweeping variants such as Delta and Omicron, it was also unclear if the specific genetic diversity circulating in the African region may have contributed 134 to the heterogeneous incidence and mortality observed<sup>8,9,10</sup>. It is therefore important to 135 characterise the genomic epidemiology of SARS-CoV-2 in Nigeria over the course of the 136 137 pandemic, to improve our understanding of what variants emerged to dominate the different 138 epidemic waves. It is also important to improve our understanding of the drivers of transmission in the region, as this remains understudied in Africa and findings from other 139 regions may not be generalizable<sup>9,11</sup>. Nigeria is highly connected to its neighbouring 140 141 countries and the wider region, potentially acting as a dominant source of transmission via 142 the high volume of movement across land as well as air borders<sup>12</sup>.

143 Several SARS-CoV-2 variants, which have a constellation of mutations that are biologically significant to the virus, emerged during the pandemic<sup>9,13,14</sup>. The B.1.525 (Eta) and B.1.1.318 144 145 variants of interest (VOIs) dominantly co-circulated with the Alpha variant during the second 146 wave in Nigeria from December 2020 to March 2021<sup>2</sup>. B.1.525 and B.1.1.318 were suggested to have emerged in Nigeria based on epidemiological reports from travellers in 147 countries such as the UK, India, Mauritius, Canada, and Brazil<sup>15,16,17,18,19</sup>. Notably, B.1.525 148 149 and B.1.1.318 both showed a significant increase in the infectivity of human and monkey cell lines experimentally, raising concerns of intrinsic increased transmissability<sup>20</sup>. Both of these 150 151 lineages also share the well-characterised E484K substitution in the Spike protein receptor-152 binding domain (RBD), which effectively reduces antibody neutralisation<sup>21</sup>.

In this study, we examine the genomic epidemiology of SARS-CoV-2 in Nigeria from March 153 154 2020 to September 2021, across the first three epidemic waves. In particular, we investigate 155 the timing and origin of the emergence of the B.1.525 and B.1.1.318 VOIs. In 156 phylogeographic reconstructions, we characterized the source-sink profiles of these best-157 sampled VOIs to better understand the bidirectional transmission dynamics of SARS-CoV-2 158 in Nigeria and the wider region. We compare our findings from our genomic data to 159 integrated travel and epidemiological data to explore the role of Nigeria's regional and 160 intercontinental connectivity in the estimated import and export dynamics.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 162 **Results**

163

#### 164 Lineage dynamics of SARS-CoV-2 in Nigeria over the first three epidemic waves 165

We generated a total of 1577 genomes from samples obtained between March 2020 and September 2021, across the first three waves of the pandemic (Fig. 1A and B). We collected samples from 25 of the 36 states and the Federal Capital Territory of Nigeria (Fig. 1C). The northern states were highly undersampled relative to the southern states, with sampling highly uneven across time (Fig. 1A and B).

171

172 To investigate the lineage dynamics across the different outbreak waves, we used the pangolin 173 nomenclature tool to assign all sequences to corresponding lineages. We detected more than 174 35 lineages across the first three waves (Fig. 1D). We found that a number of ancestral lineages 175 circulated during the first wave, including A, B, B.1, and B.1.1 (Fig. 1D). The onset of community 176 transmission in Nigeria was initially delayed, with the first wave initiated two months after the 177 first case detection in March 2020. A nationwide lockdown and ban on local and international air 178 travel were enforced, with the first wave ending in August 2020 after four months (Fig. 1B). 179 During the lockdown, we found that there was up to a 50% decline in activity at workplaces, 180 retail, supermarkets, and public transport stations, and up to a 25% increase in residential 181 activity (Fig. 1E).


182

After this strictly adhered-to lockdown, Nigeria opened its airspace to international traffic in October 2020. This was shortly followed by an increase in new cases in November 2020, marking the start of the second wave (Fig. 1B), which was characterised by B.1.1.7, B.1.525, B.1.1.318 (VOC and VOI), and other variants such as L.3 and B.1.1.487 (Fig. 1D).

187

188 Our secondary analysis focused on the lineages (B.1.525 and B.1.1.318) that contributed to the 189 surge during the second wave and have also been shown to possess genotypic traits for 190 increased transmissibility and also increased virulence in human and animal cell lines, such as 191 the E484K spike protein RBD mutation. We excluded B.1.1.7 from our analysis as it has already 192 been well studied<sup>22,23</sup>, and it was not the dominant variant in Nigeria during the second wave, unlike in other places where it was reported, such as the UK and the USA<sup>24,25,26</sup>. Moreso, the 193 second wave began after travel restrictions were lifted and human mobility was back to normal, 194 thus the need to investigate the emergence of B.1.1.318 and B.1.525 in Nigeria. The third wave 195 196 was initiated in June 2021, with the Delta variant (B.1.617.2) and its sub-lineages sweeping to 197 dominance in sampling (Fig. 1B and D). In the secondary analysis described in this work, we 198 also sought to identify the timings of emergence and number of introductions of these VOI.

It is made available under a CC-BY-NC-ND 4.0 International license .



#### 199 200

201 Fig. 1: Genomic epidemiology of SARS-CoV-2 in Nigeria. A) Reported daily news Epicurve of SARS-202 CoV-2 cases in Nigeria (blue bars) in Nigeria and genomes produced assembled during the first three 203 waves (red line) with the y-axis transformed to a log-scale. B) Time-varying sampling fraction of genomes 204 produced in this study per new cases **C**) Geographic distribution of sequences generated in the current 205 study. The map of Nigeria shows the number of genomes from states across the country as region colour 206 and marker size display lineages per state. D) Lineage frequency profile for the study period. The 207 frequency of PANGO lineages across the country over a period of 80 weeks. Lineages that are not VOCs 208 or VOIs, or that do not appear more than three times over the course of the pandemic, are grouped as 209 "others". E) Human mobility data from Google for retail shops, pharmacies, parks, public transport, 210 workplaces, and residential activity places from January 2020 to November 2021, as compared to the 211 pre-pandemic baseline (January to February, 2021).

- 212
- 213

#### 214 Regional connectivity drove the introduction of B.1.1.318 into Nigeria.

215

Using Bayesian phylogeographic reconstructions, we investigated the timing and origin of the B.1.1.318 emergence to better understand Nigeria's connectivity in the global SARS-CoV-2

218 transmission networks (see Methods). B.1.1.318 was first detected in Nigeria in Lagos State in

It is made available under a CC-BY-NC-ND 4.0 International license .

December 2020. The lineage was detected in multiple countries within and outside Africa,
 notably resulting in a large outbreak in Mauritius<sup>19</sup>.

221

222 In our phylogeographic reconstruction, we found that B.1.1.318 emerged in Africa (root state 223 posterior support = 0.95-6) in early August [mean tMRCA = 5 August, 95% HPD 25 June to 20 224 September] across two replicates (Fig. 2A). We estimated that B.1.1.318 was introduced to 225 Nigeria on at least 53 independent occasions [mean introductions, 95% HPD 50-59] beginning 226 in November 2020, after travel restrictions were lifted in October (Fig. 2B). We found that the 227 majority of introductions originated from other African nations (Fig. 2B), indicating Nigeria's 228 strong connectivity to the region. However, the number and origin of introductions and exports 229 estimated from genomic data is sample dependent, with bidirectional transmission to and from 230 undersampled regions obscured by uneven sampling globally. To overcome this, we quantified 231 air travel patterns to and from Nigeria over time to better understand which countries were most 232 likely to act as transmission sources or sinks based on their connectivity to Nigeria.

233

234 Before travel restrictions were lifted in October 2020, we found that the low levels of incoming 235 air travel volume predominantly originated from other African nations, followed by the Middle 236 East (driven by the UAE) and Europe (driven by the UK) (Fig. 2C-D, SFigure 2). This suggests 237 that the introduction risk was predominantly driven by regional connectivity during the period 238 when travel restrictions were in place. We sought to investigate this further by guantifying the 239 introduction risk for all countries connected to Nigeria by air travel. We estimated the 240 introduction intensity index (III), which accounts for the number of cases in the source countries 241 as well as the travel volume to Nigeria (see Methods). Overall, we found that the introduction 242 risk from air travel was very low during the period of travel restrictions (May 2020 to October 243 2020), as incoming travellers originated largely from other African nations with low incidence 244 (Fig. 2F).

245


246 We found that the number of incoming air passengers peaked in December 2020 - January 247 2021 (Fig. 2C-D). We also observed that the number of inbound passengers from Europe, the 248 Middle East, and Northern America increased relative to other African nations after restrictions were lifted, resulting in comparable volumes from Africa, Europe, and the Middle East (Fig. 2C-249 D). The 30-fold increase in incoming passengers by December 2020 was reflected in the 250 corresponding peak in the III, attributable to increased introduction risk from Europe and North 251 252 America from November 2020 into early 2021 (Fig. 2F). The surge was predominantly driven by 253 the high-incidence second waves of the UK and USA, respectively (SFigure 1).

254

255 We found that the III peak but not the estimated sources of risk were consistent with the number 256 and origin of introductions of B.1.1.318 in our phylogeographic reconstructions (Fig. 2B). We estimated the highest introduction risk for Europe after travel restrictions were lifted, whereas 257 258 the majority of introductions estimated from genomic data originated in other African countries. The III from other African nations was relatively low, despite comparable incoming air travel 259 260 volume. This is likely both a factor of the relatively low incidence in most African countries 261 during this period (Fig. 2F, SFigure 3) as well as the fact that our travel data does not account 262 for land-based travel, which will expectedly severely underestimate the introduction risk from

surrounding countries. The III from the African region was largely driven by South Africa, which was experiencing a peaked incidence from its second wave (SFigure 3). In our III analyses, we found negligible introduction risk from outside of Europe and North America.

266



267

268 Fig. 2: A) Time-resolved B.1.1.318 phylogeny. Branches are coloured by region-level geographic state 269 reconstruction. Internal nodes annotated with black points represent posterior support > 0.75. B) Mean 270 number of introductions (Markov jumps) of B1.1.318 into Nigeria from all source regions, binned by 271 month. The mean number of introductions overall (inset). C) Volume of monthly air passengers inbound 272 to Nigeria across 2020-2021 by source region (bar, left axis) and fold increase in travel volume compared 273 to May 2020 baseline. D) Estimated Introduction Intensity Index for Nigeria from 2020-2021. E) 274 Percentage of inbound air travel to Nigeria by source region across 2020-2021. See Supplementary 275 Figure 2 for country-level data.

#### 276 The Eta variant of interest (B.1.525) likely emerged in Nigeria.

277

The B.1.525 (Eta) lineage drove the second wave from January to March 2021. B.1.525 was 278 initially reported to have originated in Nigeria or the UK<sup>16,17,18</sup>. We investigate the timing, origin, 279 and transmission dynamics of B.1.525 with Bayesian phylogeographic reconstructions (see 280 Methods). We estimated that the B.1.525 lineage emerged in Nigeria (root state posterior 281 support = 0.998) in late July [mean tMRCA 23 July, 95% HPD 7 June to 4 September], during 282 the final weeks of Nigeria's first wave (Fig. 3A). This suggests that this lineage circulated 283 284 cryptically for several months before its first detection in Nigeria on 12 December 2020, likely owing to low-incidence-associated sparse sampling (Fig. 1A). 285

286

We sought to better understand Nigeria's connectivity in global SARS-CoV-2 transmission networks by identifying the most likely destinations of B.1.525's exportation, as the lineage 1) emerged in Nigeria and 2) is Nigeria's most sampled lineage, excluding the Delta variant


290 sublineages. To investigate the spread of B.1.525 from Nigeria, we reconstructed the timing and 291 pattern of geographic transitions out of and into Nigeria across the full posterior of our Bayesian phylogeographic reconstructions. We estimated that B.1.525 was exported from Nigeria a lower 292 293 bound of 295 times [mean Markov jumps, 95% HPD 259-335] (Fig. 3B). The majority of 294 sampled exports were destined for Europe, followed by the rest of Africa and Northern America 295 from December 2020 to March 2021 (encompassing Nigeria's second wave) (Fig. 3B). During 296 this period, we also found that B.1.525 was re-introduced from Europe a lower bound of 20 297 [95% HPD 6-37] times (Fig. 3E). These estimated source-sink dynamics support Nigeria's 298 strong connectivity, particularly to Europe, but will underestimate exports to undersampled 299 regions such as neighbouring African countries. To mitigate the effect of global sampling biases 300 on genomic estimates of transmission dynamics, we again analysed changes in air travel to and 301 from Nigeria over time to understand the sources and seeds of Nigeria's bidirectional 302 transmission dynamics.

303

African nations dominated the reduced level of outbound travel during the period of travel 304 305 restrictions (May to October 2020) (Fig. 3C-D), suggesting that regional connectivity drove Nigeria's export risk during this period. We integrated the air travel data with Nigeria's epidemic 306 incidence data to quantify an exportation intensity index (EII)<sup>27</sup>. The EII quantifies the temporal 307 trend in the daily estimated number of viral exports from Nigeria to sink countries (see 308 309 Given the data available, Nigeria's estimated export intensity was low overall Methods). 310 compared to countries with high air traffic data to Nigeria, as the country's SARS-CoV-2 311 incidence remained comparatively low on a global-scale for the entire period under investigation 312 (Fig. 3F). Nigeria's first wave had relatively low incidence, peaking at about 4000 cases in a 313 week in late June (week 18) (SFigure 4B). Combined with reduced travel volumes, the period 314 from May 2020 to September 2020 was characterised by negligible export intensity (Fig. 3F). 315

316 Outbound air travel recovered gradually over 2020, peaking in December 2020 - January 2021 317 (Fig. 3C-D). We found that this peak corresponded with the peak of the larger second wave in Nigeria and therefore also the EII, as well as the distribution of exports of B.1.1.525 from Nigeria 318 (Fig. 3B, F). The proportion of outbound air travel destined for countries in Europe, the Middle 319 320 East, and North America increased relative to travel destined for African countries after travel 321 restrictions were lifted (Fig. 3C-D). We estimated the highest EII for Europe (driven 322 predominantly by travel to the UK) and Northern America (driven by travel to the USA) from 323 December 2020 to February 2021 (SFigure 4). The export intensity to Europe is consistent with 324 the high number of estimated exports in the genomic data, though North America was 325 disproportionately underestimated in the genomic data (Fig. 3B). Overall, air travel volume 326 destined for Europe was only moderately higher (10%) than Africa, North America, and the 327 Middle East from December (after first detection and at the start of the second wave) to April 328 2021 (end of the second wave) (Fig. 3C-D). However, Europe had 4-fold more sampled 329 introductions of B.1.525 than African nations or the USA. Notably, the comparatively high EII for 330 the Middle East region (representing 20% of outbound volume overall) was not represented in 331 our phylogeographic reconstructions (Fig. 3B). This highlights how unevenly distributed 332 surveillance capacity can lead to an underestimation of transmission events (SFigure 3A).

- 333
- 334



335 336 Fig. 3: A) Time-resolved B.1.525 phylogeny. Branches are coloured by region-level geographic state 337 reconstruction. Internal nodes annotated with black points represent posterior support > 0.75. B) Mean 338 number of exports (Markov jumps) of B.1.525 from Nigeria to destination regions, binned by month. Mean 339 number of exports overall (inset). C) Volume of monthly air passengers outbound from Nigeria across 340 2020 - 2021 by destination region (bar, left axis) and fold increase in travel volume compared to baseline 341 (May 2020). D) Percentage of outbound air travel from Nigeria by destination region across 2020-2021. 342 See Supplementary Figure 1 for country-level data. E) Mean number of introductions (Markov jumps) of 343 B1.525 into Nigeria from all origin regions, binned by month. The mean number of introductions overall 344 (inset). F) Estimated Exportation Intensity Index (EII) for Nigeria from 2020-2021.

- 345
- 346

#### 347 **Discussion**

348

349 In this study, we combined genomic, travel and epidemiological data to characterise the 350 emergence and bidirectional transmission of two focal variants of interest in Nigeria. The focal VOIs, B.1.525 and B.1.1.318, were suggested to have emerged in Nigeria before spreading 351 globally, resulting in large-scale outbreaks in Brazil and Mauritius<sup>15,19</sup>. In our phylogeographic 352 reconstructions, we found that the B.1.1.318 lineage most likely emerged in the African region in 353 354 early August 2020, with its dominance in Nigeria driven by multiple introductions during the 355 second wave from November 2020 onwards. Our import risk index underestimates the 356 importance of regional connectivity in driving these introduction estimates, as they likely result 357 from shorter distance connectivity to surrounding countries, which we could not collect data on. 358 We also found that the Eta variant (B.1.525) emerged in Nigeria in late July, with high levels of 359 export to Europe reflected in the genomic and estimated export index.

360

The true extent of bidirectional transmission with other African nations will be severely underestimated in phylogeographic reconstructions, as Africa remains disproportionately undersampled despite heroic efforts<sup>28</sup>. Our findings should be interpreted in the light of our own sampling fraction, which was 0.026%. We attempted to mitigate these global surveillance biases by supplementing genomic estimates with sampling-independent metrics like the introduction

It is made available under a CC-BY-NC-ND 4.0 International license .

and export intensity indices. However, these metrics are dependent on epidemiological incidence and will be underestimated if there is large-scale underascertainment in source countries, as previously shown for African (and other) nations based on excess mortality data<sup>29,30,31</sup>.

370

371 At an unprecedented speed (72 hours from receiving the sample), ACEGID generated the first 372 whole-genome sequence of the virus in Africa in March 2020. This catalysed and built 373 confidence in SARS-CoV-2 genomic sequencing on the African continent. This immense 374 collaborative effort, involving seventeen partner laboratories in Nigeria, helped to characterise 375 the pandemic in near real-time during its first three waves in the country. As we have learnt the 376 hard way in recent years, novel variants of interest or concern can emerge from anywhere around the world, notably including undersampled regions such as Africa<sup>13,14</sup>. In a highly 377 378 connected world, there is a proactive need to adopt early warning systems for pandemic preemption and response in Africa, such as SENTINEL<sup>32</sup>. This would enable equality in global 379 380 genomic surveillance, especially in countries with fragile public health systems, in order to 381 effectively detect and curb emerging outbreaks before they spread.

382

## 383 Methods

384

#### 385 Sample preparation

386

RNA was extracted from nasopharyngeal swabs in viral transport media and saliva/sputum in
PBS using the QiAmp viral RNA mini kit (Qiagen) according to the manufacturer's instructions
and MagMax pathogen RNA/DNA kit (Applied Biosystems) using a Kingfisher Flex purification
system (ThermoFisher Scientific) according to the manufacturer's instructions.

391

#### 392 Probe-based SARS-CoV-2 real-time RT-PCR

393

RT-qPCR screening of suspected samples was carried out targeting N, ORF1ab and RdRP
genes of the virus using commercially available kits: genesig® (Primerdesign Ltd, UK),
DaAnGene (Daan Gene Co., Ltd, China), Liferiver (Shanghai ZJ Bio-Tech Co., Ltd, China),
Genefinder (OSANG Healthcare Co., Ltd, Korea), and Sansure (Sansure Biotech Inc., China).

398

## 399 SARS-CoV-2 whole-genome sequencing

400

401 Samples with moderate to high viral load detected with RT-qPCR (Ct value < 30) were selected 402 for sequencing, which were samples collected from genomic surveillance and hospitalised 403 individuals spatially and temporally. The sampling gap was the inability to sequence samples 404 from every state during all different waves of the pandemic in Nigeria. The Illumina COVIDseq 405 protocol was used for sequencing preparation (https://www.illumina.com/products/by-406 type/clinical-research-products/covidseq-assay.html). RNA was converted to cDNA, followed by 407 tiling amplification (400 bp) with Artic V3 primer pools, which covers the whole genome of the 408 virus. Nextera DNA flex libraries were made from the amplicons. Libraries were pooled and 409 sequenced on the Illumina MiSeq, NextSeq 2000, and NovaSeq 6000 platforms at the African 410 Center of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, 411 Ede, Nigeria.

- 412
- 413 Genome Assembly

It is made available under a CC-BY-NC-ND 4.0 International license .

We used the viral-ngs pipeline v2.1.19 (<u>https://github.com/broadinstitute/viral-ngs</u>) for demultiplexing, quality control, and genome assembly, consistent with prior work<sup>33,34,35</sup>. The demux\_plus applet of viral-ngs was used for demultiplexing basecalls to BAM files. Genome assembly was carried out using the assemble\_refbased workflow on the viral-ngs pipeline which maps each unmapped BAM file to the SARS-CoV-2 reference genome (NC\_045512.2) to generate coverage plots and FASTA files of successfully assembled genomes.

421 422

#### 423 Lineage/clade assignment

424

We used Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN)<sup>36</sup> to identify the lineages of SARS-CoV-2 circulating within Nigeria and to identify the lineages circulating in specific states of Nigeria. Nextclade (<u>https://clades.nextstrain.org/</u>) was used to assign the sequences to globally circulating viral clades and to investigate mutations in the genome that could affect primer amplification during PCR.

430

# 431 Maximum likelihood phylogenetic analysis432

433 1,577 genomes with sequence length  $\ge 20,930$  (covering 70% or more of the reference -434 NC\_045512.2) were assembled and aligned using MAFFT<sup>37</sup>. We used IQTREE<sup>38</sup> and the GTR 435 (generalised time-reversible) model with a bootstrap value of 1000 to construct the phylogenetic 436 tree. Treetime<sup>39</sup> was used for quantifying the molecular clock and identifying ancestral 437 phylogeny in the augur pipeline of Nextstrain<sup>40</sup>.

438

# 439 Bayesian phylogenetic analysis440

441 All B.1.1.318 (n = 3,858 with major locations: Europe, USA, and Africa accounting for 94%) and 442 B.1.525 (n = 8.278 with major locations: Europe, USA, and Africa accounting for 86%) sequences were downloaded from  $GISAID^{41}$  on 18 August 2021. Sequences with > 5% 443 ambiguous nucleotides, a length < 95%, or incomplete dates were discarded. Sequences were 444 445 aligned to the reference (NC 045512.2) using minimap2, with the 5' and 3' UTRs and known problematic sites (GitHub - W-L/ProblematicSites\_SARS-CoV2 3) masked<sup>42</sup>. Both lineage-446 447 specific datasets were downsampled for representativeness and computational tractability with a phylogenetic-informed downsampling scheme. A maximum-likelihood phylogenv was 448 reconstructed for each lineage with automatic model selection in IQTREE<sup>43</sup>. The phylogeny was 449 450 downsampled by root-to-tip tree-traversal, with all internal nodes subject to two rules: 1) if 95% 451 of the leaves subtended by the internal node represented a single country, the earliest 452 representative was retained alongside a random sequence; 2) if leaves from the same location 453 were separated by a zero-branch length, the earliest representative was retained alongside a 454 random sequence. All countries with more than the median number of sequences across countries were then downsampled randomly to the median, this yielded a total number of 1,118 455 456 and 1,746 genomes for B.1.1.318 and B.1.525 respectively. All Nigerian sequences were retained (n = 73 for B.1.1.318; n = 256 for B.1.525). 457

458

We reconstructed Bayesian time-scaled phylogenies for each lineage using BEAST 1.10.5<sup>44</sup>. For both lineages, the time-scaled phylogenies were reconstructed under an HKY substitution model with a gamma-distributed rate for variation among sites<sup>45</sup>, a relaxed molecular clock with a log-normal prior<sup>46</sup>, and an exponential growth coalescent tree prior<sup>47</sup>. For each dataset, we combined two independent Markov Chain Monte Carlo (MCMC) chains of 200 million states, run with the BEAGLE package<sup>48</sup> to improve run time. Parameters and trees were sampled every 20,000 steps, with the first 20% of steps discarded as burn-in. Convergence and mixing of the

466 MCMC chains were assessed in Tracer v1.7, to ensure the effective sample size (ESS) of all 467 estimated parameters was >  $200^{49}$ .

468

469 We performed an asymmetric discrete trait analysis using BEAST version 1.10.5 to reconstruct 470 the location-transition history across an empirical distribution of 4000 time-calibrated trees (sampled from each of the posterior tree distributions estimated above). We aggregated the 471 472 country of sampling on a regional level for computational tractability. We used Bayesian 473 stochastic search variable selection (BSSVS) to infer non-zero migration rates and identify the 474 statistically supported transition routes into and out of Nigeria by a Bayes factor test<sup>50</sup>. In addition to the discrete trait analysis, we used a Markov jump counting approach to estimate the 475 476 timing and origin of geographic transitions into Nigeria to account for uncertainty in 477 phylogeographic reconstruction associated with sparse sampling and low sequence variability<sup>51</sup>. 478 We used the TreeMarkovJumpHistoryAnalyzer from the pre-release version of BEAST 1.10.5 to extract the Markov jumps from posterior tree distributions<sup>52</sup>. We used TreeAnnotator 1.10 to 479 construct Maximum clade credibility (MCC) trees for all datasets. Trees were visualised using 480 481 baltic (https://github.com/evogytis/baltic).

482

#### 483 Air traffic and human movement data

484

485 In order to associate international air travel and local human movement with variant movement 486 across borders, we used air traffic data from the International Air Transportation Association 487 (IATA) obtained from BlueDot (https://bluedot.global/) to quantify the volume of international 488 travellers to and from Nigeria. The dataset included the number of travellers by origin and 489 destination country, aggregated by month, across all international airports in Nigeria. Data was 490 obtained for the period May 2020 to April 2021, encompassing the emergence and spread of B.1.525 and B.1.1.318. We also curated human movement data within Nigeria from Google 491 492 Mobility (https://www.google.com/covid19/mobility/) from January 2020 to November 2021, 493 which reflects a baseline before lockdown (January - March 2020) and the study's period of 494 interest. We used R to display movement patterns after grouping human movement into six 495 divisions: retail & recreation, grocery & pharmacy, parks, transport stations, workplaces, and 496 residential areas.

497

#### 498 Estimated introduction and exportation intensity index


499 500 From genomic data, estimates of the number and origin/destination of bidirectional 501 transmissions with Nigeria are dependent on the sample's representativeness of the population 502 and are therefore limited by global and local sampling biases. To limit these sampling biases, we supplemented our phylogeographic analyses by estimating the introduction (III) and export 503 intensity index (EII) according to Du Plesis et al<sup>27</sup>. The III estimates the daily risk of introductions 504 505 into Nigeria from each country as a product of the number of asymptomatically infected 506 individuals in each source country on that day (estimated from the time series of deaths) and 507 their likelihood of traveling to Nigeria (based on the volume of inbound air travel from the source 508 country). The EII is calculated similarly, based on the number of asymptomatically infected 509 individuals in Nigeria and their likelihood of travel to each destination by air. Notably, we could 510 not obtain data for land-based travel. Connectivity to regional and neighbouring countries and 511 the associated introduction and export intensity are therefore likely severely underestimated. A 512 time series of reported deaths for each country were collected from the outbreak.info R

It is made available under a CC-BY-NC-ND 4.0 International license .

513 package<sup>53</sup>. As air travel data was aggregated by month, we conservatively assumed that travel 514 was uniform across all days of the month. We quantified the III and EII for the period May 2020

515 to April 2021, encompassing the emergence and spread of B.1.525 and B.1.1.318.


It is made available under a CC-BY-NC-ND 4.0 International license .



# 526 Supplementary figures

527 528 **SFigure 1:** COVID-19 new cases per week as seen in Nigeria and countries with highest flight traffic in 529 and out of Nigeria from the four major connected regions with the y-axis transformed to a log scale. 530


It is made available under a CC-BY-NC-ND 4.0 International license .



538 539

- - - -

It is made available under a CC-BY-NC-ND 4.0 International license .




541 **SFigure 3:** Population adjusted rolling average of new daily cases for countries with the highest incoming

543 air travel as per Figure S2.

544

It is made available under a CC-BY-NC-ND 4.0 International license .



547 Concests Weeker States
 548 SFigure 4: Percentage of outgoing travel to the four major connected regions by country as per Figure 4
 549

It is made available under a CC-BY-NC-ND 4.0 International license .

## 560 Acknowledgements

561

562 This work is made possible by the support provided to ACEGID by a cohort of generous donors 563 through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll 564 Foundation, and Open Philanthropy. This work was also partly supported by grants from the 565 National Institute of Allergy and Infectious Diseases (https://www.niaid.nih.gov), NIH-H3Africa 566 (https://h3africa.org) (U01HG007480 and U54HG007480), the World Bank (projects ACE-019 and ACE-IMPACT), the Rockefeller Foundation (Grant #2021 HTH), the Africa CDC through the 567 African Society of Laboratory Medicine [ASLM] (Grant #INV018978), the Wellcome Trust 568 569 (Project 216619/Z/19/Z), the WARN-ID/CREID grant # U01AI151812, and the Science for Africa 570 Foundation.

- 571 We want to especially thank the Redeemer's University Management, the State Government of 572 Osun and NCDC for their support during the course of the COVID-19 pandemic.
- 573 574

## 575 **References**

576

577 1. World Bank, World Development Indicators (2022). Available at: http://wdi.worldbank.org/tables
578 (Accessed: 29th April 2022).

579

580 2. Tsueng G, Mullen J, Alkuzweny M, Cano M, Benjamin HR, Emily O, Curators L, Alaa A, Zhou X, Qian
581 Z, Andersen KG. Outbreak. info Research Library: A standardized, searchable platform to discover and
582 explore COVID-19 resources and data. BioRxiv. 2022 Feb 1.

583

3. Nordling L. The pandemic appears to have spared Africa so far. Scientists are struggling to explain
why. Science (80-). 2020 Aug 11;

- 4. Kreier F. Morgue data hint at COVID's true toll in Africa. Nature. 2022 Mar 23.
- 588

591

586

5. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. Nature Reviews Immunology. 2021Aug;21(8):469-70.

6. Gilbert, M., Pullano, G., Pinotti, F., Valdano, E., Poletto, C., Boëlle, P.Y., d'Ortenzio, E., Yazdanpanah,
Y., Eholie, S.P., Altmann, M. and Gutierrez, B., 2020. Preparedness and vulnerability of African countries
against importations of COVID-19: a modelling study. *The Lancet*, *395*(10227), pp.871-877.

596 7. Borrega, R., Nelson, D.K., Koval, A.P., Bond, N.G., Heinrich, M.L., Rowland, M.M., Lathigra, R., Bush,
597 D.J., Aimukanova, I., Phinney, W.N. and Koval, S.A., 2021. Cross-reactive antibodies to SARS-CoV-2
598 and MERS-CoV in pre-COVID-19 blood samples from Sierra Leoneans. *Viruses*, *13*(11), p.2325.

599

8. Bugembe DL, Phan MV, Ssewanyana I, Semanda P, Nansumba H, Dhaala B, Nabadda S, O'Toole
ÁN, Rambaut A, Kaleebu P, Cotten M. Emergence and spread of a SARS-CoV-2 lineage A variant (A.
23.1) with altered spike protein in Uganda. Nature microbiology. 2021 Aug;6(8):1094-101.

603

9. Butera Y, Mukantwari E, Artesi M, O'Toole ÁN, Hill V, Rooke S, Hong SL, Dellicour S, Majyambere O,
Bontems S, Boujemla B. Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of
incoming travelers on lineage diversity. Nature communications. 2021 Sep 20:12(1):1-1

- 606 incoming travelers on lineage diversity. Nature communications. 2021 Sep 29;12(1):1-1.
- 607

It is made available under a CC-BY-NC-ND 4.0 International license .

10. Wilkinson E, Giovanetti M, Tegally H, San JE, Lessells R, Cuadros D, Martin DP, Rasmussen DA,
Zekri AR, Sangare AK, Ouedraogo AS. A year of genomic surveillance reveals how the SARS-CoV-2
pandemic unfolded in Africa. Science. 2021 Oct 22;374(6566):423-31.

- 612 11. Parker E, Anderson C, Zeller M, Tibi A, Havens JL, Laroche G, Benlarbi M, Ariana A, Robles-Sikisaka
  613 R, Latif AA, Watts A. Regional connectivity drove bidirectional transmission of SARS-CoV-2 in the Middle
  614 East during travel restrictions. Nature communications. 2022 Aug 15;13(1):1-4.
- 615

- 616 12. Bogoch II, Creatore MI, Cetron MS, Brownstein JS, Pesik N, Miniota J, Tam T, Hu W, Nicolucci A,
  617 Ahmed S, Yoon JW. Assessment of the potential for international dissemination of Ebola virus via
  618 commercial air travel during the 2014 west African outbreak. The Lancet. 2015 Jan 3;385(9962):29-35.
  619
- 13. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San
  EJ, Msomi N, Mlisana K. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021
  Apr;592(7854):438-43.
- 14. Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J., Bester,
  P.A., Boni, M.F., Chand, M. and Choga, W.T., 2022. Rapid epidemic expansion of the SARS-CoV-2
  Omicron variant in southern Africa. *Nature*, *603*(7902), pp.679-686.
- 628 15. Pereira, F. et al. Genomic surveillance activities unveil the introduction of the SARS-CoV-2 B.1.525
  629 variant of interest in Brazil: Case report. *Journal of Medical Virology*, 93, 9, 5523–5526 (2021).
  630
- 631 16. Dresch, M. Nigerian Covid-19 variant under investigation with 38 new cases found.
  632 https://www.mirror.co.uk/news/uk-news/breaking-nigerian-covid-19-variant-23511168 (2021) (Accessed
  633 24th March, 2022).
- 634 17. Vadlapatla, S. B.1.525 Variant Linked to Nigeria now Found in Telangana 635 https://timesofindia.indiatimes.com/city/hyderabad/b-1-525-variant-linked-to-nigeria-now-found-in636 telangana/articleshow/83133727.cms. (2021) (Accessed 24th March, 2022).
- 18. Takeuchi C. COVID-19 in B.C.: New variant from Nigeria detected, ski awareness campaign
   launched, and more. https://www.straight.com/covid-19-pandemic/february-12-coronavirus-update-bc-
- vancouver-new-variant-from-nigeria-detected-ski-awareness-campaign-and-moreTakeuchi.
   (2021)
   (Accessed 24th March, 2022).
- 641
- 642 19. Tegally, H. et al. A novel and expanding SARS-CoV-2 Variant, B. 1.1. 318, dominates infections in
  643 Mauritius. *medRxiv* https://doi.org/10.1101/2021.06.16.21259017 (2021).
  644
- 20. Zhang L, Cui Z, Li Q, Wang B, Yu Y, Wu J, Nie J, Ding R, Wang H, Zhang Y, Liu S. Ten emerging
  SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
  Communications biology. 2021 Oct 13;4(1):1-0.
- 648
- 649 21. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M,
  650 Hoffmann HH, Michailidis E, Gaebler C. Escape from neutralizing antibodies by SARS-CoV-2 spike
  651 protein variants. Elife. 2020 Oct 28;9:e61312.
  652
- 22. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong S,
  Silk BJ, Armstrong GL, Biggerstaff M. Emergence of SARS-CoV-2 b. 1.1. 7 lineage—united states,
  december 29, 2020–january 12, 2021. Morbidity and Mortality Weekly Report. 2021 Jan 1;70(3):95.
- 657 23. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton
  658 S, Clutterbuck EA. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of

It is made available under a CC-BY-NC-ND 4.0 International license .

concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. The Lancet. 2021
 Apr 10;397(10282):1351-62.

661

662 24. Chaillon, A. & Smith, D. M. Phylogenetic analyses of SARS-CoV-2 B.1.1.7 lineage suggest a single
663 origin followed by multiple exportation events versus convergent evolution. *Clinical Infectious Diseases*664 73, 12, 2314–2317 (2021).

665
666 25. Washington, N. L. et al. (2021). Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the
667 United States. *Cell* 184, 10, 2587-2594.

668

- 26. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. *Science* 372, 6538, eabg3055 (2021).
- 672 27. du Plessis, L. et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK.
  673 *Science (New York, N.Y.)*, **371**, 6530, 708–712 (2021).
  674
- 675 28. Tegally H, San JE, Cotten M, Tegomoh B, Mboowa G, Martin DP, Baxter C, Moir M, Lambisia A,
  676 Diallo A, Amoako DG. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding
  677 genomic surveillance. medRxiv. 2022 Jan 1.

678

- 679 29. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, Moyes J, McMorrow ML,
  680 Kahn K, Gómez-Olivé FX, Tollman S. SARS-CoV-2 Seroprevalence in a rural and urban household
  681 cohort during first and second waves of infections, South Africa, July 2020–March 2021. Emerging
  682 infectious diseases. 2021 Dec;27(12):3020.
- 30. Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, Aravkin AY, Bisignano C, Barber
  RM, Alam T, Fuller JE. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis
  of COVID-19-related mortality, 2020–21. The Lancet. 2022 Apr 16;399(10334):1513-36.
- 31. Cohen C, Kleynhans J, von Gottberg A, McMorrow ML, Wolter N, Bhiman JN, Moyes J, du Plessis M,
  Carrim M, Buys A, Martinson NA. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an
  urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. The Lancet Infectious
  Diseases. 2022 Mar 14.
- 692

693 32. Botti-Lodovico, Y. et al. The Origins and Future of Sentinel: An Early-Warning System for Pandemic
694 Preemption and Response. *Viruses* 13, 8, 1605 (2021).

- 33. Siddle, K. J. et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in
  2018. *The New England Journal of Medicine* **379**, 18, 1745–1753 (2018).
- 697 34. Ajogbasile, F. V. et al. Real-time metagenomic analysis of undiagnosed fever cases unveils a
  698 yellow fever outbreak in Edo State, Nigeria. *Scientific Reports* **10**, 1, 1-6 (2020).
- 35. Oluniyi, P. First African SARS-CoV-2 genome sequence from Nigerian COVID-19 case.
  Virological https://virological.org/t/first-african-sars-cov-2-genome-sequence-from-nigerian-covid-19case/421 (2020).
- 36. Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
   epidemiology. *Nat Microbiol* https://doi.org/10.1038/s41564-020-0770-5 (2020).
- 705
  706 37. Katoh, K., Misawa, K., Kuma, K., & Miyata, T. MAFFT: a novel method for rapid multiple sequence
  707 alignment based on fast Fourier transform. *Nucleic Acids Research*, **30**, 14, 3059–3066 (2002).
  708
- 709 38. Minh, B.Q., Schmidt, H.A., Chernomor, O., Schrempf, D., Woodhams, M.D., von Haeseler, A. &
- Lanfear, R. IQ-TREE 2: New models and efficient methods for phylogenetic inference in the genomic era.
- 711 Mol. Biol. Evol. 37, 1530-1534 (2020).

It is made available under a CC-BY-NC-ND 4.0 International license .

712 713 39. Sagulenko, P., Puller, V. & Neher, R.A. TreeTime: Maximum-likelihood phylodynamic analysis. Virus 714 *Evol.* **4**, 1, vex042 (2018). 715 716 40. Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, 717 T. & Neher, R. A. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics (Oxford, England), 718 **34,** 23, 4121–4123 (2018). 719 720 41. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative contribution to 721 global health. Global Challenges, 1, 33-46 (2017). 722 723 42. Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics, 34, 18, 3094-3100 724 (2018). 725 726 43. Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K., Von Haeseler, A. & Jermiin, L. S. ModelFinder: fast 727 model selection for accurate phylogenetic estimates. Nature methods, 14, 587-589 (2017). 728

- 44. Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J. & Rambaut, A. Bayesian
  phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus evolution*, 4, 1, vey016 (2018).
- 45. Hasegawa, M., Kishino, H. & Yano, T. A. . Dating of the human-ape splitting by a molecular clock of
  mitochondrial DNA. *Journal of Molecular Evolution*, 22, 2, 160-174 (1985).
- 735 46. Drummond, A. J., Ho, S. Y. W., Phillips, M. J. & Rambaut, A. Relaxed phylogenetics and dating with
  736 confidence. *PLoS Biology*, 4, 5, e88 (2006).
  737
- 47. Drummond, A. J., Rambaut, A., Shapiro, B. E. T. H. & Pybus, O. G. Bayesian coalescent inference of
  past population dynamics from molecular sequences. *Molecular Biology and Evolution*, 22, 5, 1185-1192
  (2005).
- 48. Ayres, D. L. et al. BEAGLE: an application programming interface and high-performance computing
  library for statistical phylogenetics. *Systematic Biology*, **61**, 1, 170-173 (2012).
- 49. Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior summarization in
  Bayesian phylogenetics using Tracer 1.7. *Systematic Biology*, 67(5), 901 (2018).
- 50. Lemey, P., Rambaut, A., Drummond, A. J. & Suchard, M. A. Bayesian phylogeography finds its roots. *PLoS Computational Biology*, *5*, 9, e1000520 (2009).
- 51. Worobey, M. et al. The emergence of SARS-CoV-2 in Europe and North America. *Science*, **370**, 6516, 564-570 (2020).
- 52. Lemey, P. et al. Untangling introductions and persistence in COVID-19 resurgence in Europe. *Nature*,
  595, 7869, 713-717 (2021).
- 53. Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, Haag E, Zeller M, Aceves
  CM, Zaiets K, Cano M. Outbreak. info genomic reports: scalable and dynamic surveillance of SARS-CoV2 variants and mutations. Research square. 2022 Jan 1.
- 760
- 761

750

753